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Abstract
Air Pollution has been associated with significant adverse health effects leading to increased morbidity and
mortality. Cumulative epidemiological and experimental data have shown that exposure to air pollutants
lead to increased cardiovascular ischemic events and enhanced atherosclerosis. It appears that these
associations are much stronger with the air particulate matter (PM) component and that in urban areas,
the smaller particles could be more pathogenic, as a result of their greater propensity to induce systemic
prooxidant and proinflammatory effects. Much is still unknown about the toxicology of ambient
particulates as well as the pathogenic mechanisms responsible for the induction of adverse cardiovascular
health effects. It is expected that better understanding of these effects will have large implications and may
lead to the formulation and implementation of new regulatory policies. Indeed, we have found that
ultrafine particles (<0.18 μm) enhance early atherosclerosis, partly due to their high content in redox
cycling chemicals and their ability to synergize with known proatherogenic mediators in the promotion of
tissue oxidative stress. These changes take place in parallel with increased evidence of phase 2 enzymes
expression, via the electrophile-sensitive transcription factor, p45-NFE2 related transcription factor 2
(Nrf2). Exposure to ultrafine particles also results in alterations of the plasma HDL anti-inflammatory
function that could be indicative of systemic proatherogenic effects. This article reviews the
epidemiological, clinical and experimental animal evidence that support the association of particulate
matter with atherogenesis. It also discusses the possible pathogenic mechanisms involved, the
physicochemical variables that may be of importance in the greater toxicity exhibited by a small particle
size, interaction with genes and other proatherogenic factors as well as important elements to consider
in the design of future mechanistic studies.
Extensive epidemiological evidence supports the association of air pollution with adverse health effects [1-
3]. It is increasingly being recognized that such effects lead to enhanced morbidity and mortality, mostly
due to exacerbation of cardiovascular diseases and predominantly those of ischemic character [4]. Indeed,
in addition to the classical risk factors such as serum lipids, smoking, hypertension, aging, gender, family
history, physical inactivity and diet, recent data have implicated air pollution as an important additional risk
factor for atherosclerosis. This has been the subject of extensive reviews [5,6] and a consensus statement
from the American Heart Association [7]. This article reviews the supporting epidemiological and animal
data, possible pathogenic mechanisms and future perspectives.
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Exposure to air particulate matter leads to 
increased cardiovascular morbidity and 
mortality
While air pollution is a complex mixture of compounds in
gaseous (ozone, CO and nitrogen oxides) and particle
phases [8], the strongest evidence among several hundred
epidemiological studies linking air pollution with human
health effects, centers around the particulate components
[7-13]. Particulate matter (PM) is comprised of heteroge-
nous compounds varying in size, number, chemical com-
position, surface area, concentration and source [7,8].
Some atmospheric particles are liquid, some are solid and
others may contain a solid core surrounded by liquid. PM
includes primary particles that are emitted directly from
sources such as fossil-fuel combustion (e.g. diesel exhaust
particles) and secondary particles that are generated from
gases through chemical reactions involving atmospheric
oxygen (O2), water vapor (H2O), reactive species such as
ozone (O3), free radicals such as hydroxyl (.OH) and
nitrate (.NO3) radicals, pollutants such as sulfur dioxide
(SO2), nitrogen oxides (NOx), and organic gases from
natural and anthropogenic sources [8].
Particles are also classified according to their aerodynamic
diameter into size fractions such as PM10 ("thoracic" par-
ticles, < 10 μm), PM2.5-10 ("coarse" particles, 2.5 to 10
μm), PM2.5 (fine particles, < 2.5 μm and UFP (ultrafine
particles, < 0.1 μm). These particles are derived from vari-
ous sources and by various mechanisms as shown in Table
1, producing distinct lognormal modes in the particle size
distributions by number and volume (nucleation, Aitken
mode, accumulation and coarse modes) (Figure 1) [8].
UFP correspond to the nucleation and Aitken modes.
They are typically derived from combustion of fossil-fuels
and are the result of nucleation of gas phase species to
form condensed phase species in newly formed particles
which have had little chance to grow (nucleation mode)
or in recently formed particles that are actively undergoing
coagulation (Aitken mode). Some particle fractions are
inclusive of others like PM2.5 which contain particles in
the nucleation and Aitken mode (UFP) as well as particles
in the accumulation mode (> 0.1 μm), where particles
grow in size and "accumulate" by coagulation (two parti-
cles combining to form one) or by condensation (gas
molecules condensing on a particle). The coarse particles
correspond to the coarse mode, typically derived from
soil, agricultural and road dust, tire wear emissions, con-
struction debris, mining operations and are mainly
formed by the mechanical breakdown (crushing, grind-
ing, abrasion of surfaces) of crustal material, minerals and
organic debris [8]. Major sources of PM2.5 include power
plants, oil refinery and metal processing facilities, wild-
fires, tailpipe and brake emissions from mobile sources,
residential fuel combusion. UFP are mostly generated
through tailpipe emissions from mobile sources (motor
vehicles, aircrafts, and marine vessels) [14].
Multiple studies show that short-term exposure to PM10
results in small increases in cardiovascular mortality.
Thus, in approximately 50 million people from NMMAPS
(National Morbidity, Mortality, and Air Pollution Study),
it was found that daily cardiopulmonary mortality
increased by 0.6% for every 20 μg/m3 increase in PM10
load [15]. This association was confirmed in Europe,
Table 1: Classification of particles based on size
Particle Aerodynamic diameter 
(μm)
Sources Mode of generation Atmospheric half-life
Thoracic particles(PM10)<  1 0 - - -
Coarse particles(PM2.5-10) 2.5 - 10 Suspension from disturbed 
soil (farming, mining, unpaved 
roads), construction, plant 
and animal fragments
Mechanical disruption 
(crushing, grinding, abrasion 
of surfaces), evaporation of 
sprays, suspension of dusts.
Minutes to hours
Fine particles (PM2.5) < 2.5 Power plants, oil refineries, 
wildfires, residential fuel 
combustion, tailpipe and 
brake emissions
Gas-to-particle conversion by 
condensation, coagulation 
(accumulation mode)
Days to weeks
Ultrafine particles (UFP) < 0.1* Fuel combustion (diesel, 
gasoline) and tailpipe 
emissions from mobile 
sources 
(motor vehicles, aircrafts, 
ships)
Fresh emissions, secondary 
photochemical reactions 
(nucleation mode)
Minutes to hours
PM10 includes all other PM fractions. * While the UFP size cutoff is by definition considered < 0.1 μm, UFP can include particles up to 0.2 μm in 
experimental studies using particle concentrators, because the distinction between the ultrafine and the accumulation modes can vary from 0.1 to 
0.2 μm depending upon location and season for reasons that include among others, variability in the size of particulate derived from "fresh" 
emission sources and deviation from a spherical shape [101]. Table based on U.S. EPA [8].Particle and Fibre Toxicology 2009, 6:24 http://www.particleandfibretoxicology.com/content/6/1/24
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where ~43 million adults in 29 European cities from the
APHEA2 (Air Pollution and Health: A European
Approach) study exhibited a 1.5% increase in daily cardi-
ovascular mortality for every 20 μg/m3 increase in PM10
[16]. However, studies have also shown that the magni-
tude of these associations are bigger with the smaller
PM2.5 fraction. Thus, 12,865 patients enrolled in IHCS
(Intermountain Heart Collaborative Study) had a daily
increase of 4.5% in acute ischemic coronary events per 10
μg/m3 increase in ambient PM2.5 [17]. Associations of air
pollution with cardiovascular events have also been dem-
onstrated in longer-term exposure studies. The latest
report of the American Cancer Society II study demon-
strated in ~500,000 adults, a 12% increase in cardiovacu-
lar deaths per 10 μg/m3 increase in long-term (annual
average) PM2.5  exposure [4]. Importantly, this study
showed that deaths from ischemic heart disease was the
single largest cause of mortality (18% increase). This asso-
ciation was even stronger in the extended analysis of the
Harvard Six Cities Study that showed a 28% increase in
cardiovascular (CV) deaths per 10 μg/m3 increase in long-
term PM2.5  exposure [18], and even stronger in the
Women Health Initiative Study [19], which showed in
65,893 post-menopasual women, a 24% and 76%
increase in the incidence of CV events and CV mortality,
respectively. It appears that as the studies have gotten bet-
ter tailored to assess CV morbility and mortality, the
strength and magnitude of associations have become
stronger. In addition, the extended analysis of the Harvard
Six Cities Study showed in 8,096 participants from six US
cities followed up over two time periods (1974 through
1989 and 1990-1998) that a decrease in CV mortality par-
alleled a decline in annual mean PM2.5 concentrations. CV
mortality exhibited a 31% reduction per each 10-μg/m3
Idealized particle size distribution that might be observed in traffic Figure 1
Idealized particle size distribution that might be observed in traffic. Particles from different sizes are generated by 
four modes: nucleation, aitken, accumulation and coarse mode. Also shown are the major formation and growth mechanisms 
of the four modes of ambient particles. V = volume, Dp = particle diameter. Source: U.S. EPA [8].Particle and Fibre Toxicology 2009, 6:24 http://www.particleandfibretoxicology.com/content/6/1/24
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improvement in city-specific mean PM2.5 in between the
two periods [18]. More importantly, the drop in the
adjusted mortality rate was largest in the cities with the
largest reductions in PM2.5, underscoring the importance
of PM monitoring, regulation and acting upon this prob-
lem, given the potential and substantial benefits in Public
Health outcomes. It has been suggested that reduction in
the level of air PM may even account for some of the
reduction observed in US mortality rates over the last 2
decades [20]. Although the epidemiological studies with
PM10 and PM2.5 data support the notion that a smaller par-
ticle size correlates with bigger cardiovascular effects,
there are few reports supporting the association of UFP
with increased total or cardio-respiratory mortality
[21,22]. Lack of studies is partly due to the difficulty of
quantifying UFP exposure due to the lack of routine air
pollution monitoring equipment to assess UFP parame-
ters.
Exposure to ambient PM leads to enhanced CV morbidity
and mortality by a variety of proposed mechanisms, sum-
marized in Figure 2. CV ischemic events may be due to a
myriad of both acute and chronic effects. Thus, acute
exposure to PM has been associated with the triggering of
acute myocardial infarction [23-25], discharge of
implanted automatic cardioverter defibrillators [26], hos-
pitalizations for acutely decompensated congestive heart
failure [27] and ischemic stroke [28]. Such acute effects
may involve prothrombotic mechanisms such as eleva-
tion of fibrinogen [29], increased platelet aggregation and
factors II, VII and X activity [30] or alterations of arterial
vasoconstriction [13], leading to greater propensity for the
development of ischemia in subjects with coronary artery
disease [31,32]. The accumulation of acute and sub-acute
effects or the chronic exposure to PM may also result in
the promotion of atherosclerosis which can be evidenced
over months or years.
The first study to find an association of PM exposure with
atherosclerosis in human subjects was performed in the
University of Southern California by Kunzli et al [33], a
cross-sectional study that included 798 individuals. They
Possible mechanisms that link air pollution with increased cardiovascular morbidity and mortality Figure 2
Possible mechanisms that link air pollution with increased cardiovascular morbidity and mortality. Air pollutants 
may trigger pulmonary reflexes that can activate the autonomic nervous system and result in alterations of heart rate variability 
and induction of dysrhythmias (in green). Air pollutants may directly affect cardiac tissue leading to the induction of dysrhyth-
mias and/or cardiomyopathy (in yellow). Air pollutants can also enhance atherothrombotic processes that lead to the develop-
ment of acute coronary syndromes (ACS) via the generation of pulmonary inflammation or direct translocation into the 
systemic circulation (in blue). Atherothrombotic processes include increased vascular oxidative stress, endothelial cell dysfunc-
tion, atherosclerosis and increased platelet aggregability and coagulation, among others.
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correlated the degree of carotid intima-media thickness
(CIMT) with levels of annual mean concentrations of
ambient PM2.5, estimated by geocoding of the subjects'
residential areas (Table 2). This study showed a 5.9%
increase in carotid intima-medial thickness for every 10
μg/m3 rise in PM2.5 levels [33]. Likewise, a prospective
German cohort study supported an association in
between long-term residential exposure to high traffic,
levels of PM2.5 and coronary atherosclerosis as assessed by
coronary artery calcification scores [34]. Hoffmann et al
found in 4,494 participants, that compared with subjects
living > 200 meters away to a major road, subjects living
within 50, 51 to 100 and 101 to 200 meters showed 63%,
34% and 8% increase in the probability of having a high
coronary artery calcification (CAC) score, respectively.
Nevertheless, the strength of associations between PM
and atherosclerosis in humans is still being debated.
While Hoffmann et al found positive associations with
the distance to a major road, there were non-statistically
significant associations with PM2.5 exposure. In addition,
data from the Multi-Ethnic Study of Atherosclerosis [35]
show some weaker associations than those shown by the
previous studies (Table 2). Hence, long-term (20-year)
exposure to PM was estimated on the basis of a residential
history and the use of a spatio-temporal model to predict
PM10  and PM2.5  exposures for each participant-month
based on the geographic location of each participant's res-
idence each month. Three measures of subclinical athero-
sclerosis, such as CIMT, coronary artery calcification and
ankle-brachial index (ABI) were employed in 5,172 US
participants. While no associations were present with
either coronary calcium or ABI measures, PM10 exposures
(20-year means and 2001 mean) and 20-year PM2.5 expo-
sures did correlate with 1-3% increase in CIMT per 21 μg/
m3 increase in PM10 or 12.5 μg/m3 increase in PM2.5,
respectively.
Based on this evidence, it would appear that PM2.5 expo-
sure may contribute to enhancement of human athero-
sclerosis, although the strength and relative importance of
this mechanism in contributing to cardiovascular morbid-
ity and mortality is still to be ascertained. Just as the
strength of the associations of PM with cardiovascular
outcomes increased when moving from PM10 to PM2.5
metrics, it has been suggested that these associations
could be even stronger with the UFP fractions for reasons
that are discussed below. Although there are no studies
available yet that have evaluated the effects of UFP expo-
sures on human atherosclerosis, recent findings from the
Southern California Particle Center (SCPC) are consistent
with the notion of UFP's greater proatherogenic potential.
Delfino et al studied residents in independent living facil-
ities of two retirement communities in Los Angeles [36].
31 subjects with history of CAD were followed up over 7-
month periods with a very detailed pollutant exposure
characterization and blood collection for the determina-
tion of systemic inflammatory, antioxidant and coagula-
tion markers. They found positive associations of particle
number (dominated by UFPs) and outdoor quasi-
ultrafine PM0.25 (< 0.25 μm) with biomarkers of systemic
inflammation such as C-reactive protein (CRP), inter-
leukin (IL-6) and soluble tumour necrosis factor receptor
II (sTNF-RII). By contrast, 4-day average outdoor accumu-
lation-mode PM0.25-2.5  showed an unexpected inverse
association instead [36]. This study is in agreement with a
previous report where exposure to UFP correlated with
increased plasma levels of soluble CD40 ligand
(sCD40L), a marker for platelet activation that reflects
increased coagulation and inflammation [37]. Thus, there
is need for human studies that evaluate the potential links
between UFP exposures and clinical measures of athero-
sclerosis.
Studies in animal models support a causal 
association for PM and atherosclerosis
Work with experimental animals have been important to
establish a causal association between exposure to PM
and atherosclerosis. The first evidence was from work at
the University of British Columbia in Ontario, Canada
[38]. Suwa et al exposed female Watanabe heritable
Table 2: Human studies linking air pollution exposure with atherosclerosis
Study Air pollutant Evaluation of atherosclerosis Major Findings Reference
Kunzli et al PM2.5
Ozone
CIMT 5.9% increased in CIMT per every 10 μg PM2.5/m3 [33]
Hoffmann et al PM2.5
Distance to major road
CACS Increased CAC scores with shorter distances to a 
major road
[34]
Diez Roux et al PM10
PM2.5
CIMT
CACS
BAI
1-3% increase in CIMT per every 21 and 12.5 μg/m3 in 
PM10 and PM2.5 respectively
[35]
CIMT = Carotid intima-media thickness, CACS = coronary artery calcium score,
BAI = Brachial artery index.Particle and Fibre Toxicology 2009, 6:24 http://www.particleandfibretoxicology.com/content/6/1/24
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hyperlipidemic rabbits to biweekly intrapharingeal instil-
lations of urban air PM10. The degree of aortic and coro-
nary atherosclerosis was evaluated by estimating the
atherosclerotic lesion volumes in sections from the vari-
ous vessels. Qualitative analysis included the assessment
of the types of plaques according to AHA guidelines
[39,40], plaque composition and cellularity. They deter-
mined that although there were no differences in the fre-
quency of plaques in either the coronaries or aorta, PM10
administration resulted in a 71% significant increase in
the relative volume of atherosclerotic lesions in the coro-
nary arteries and a 62% increase in the relative volume of
extracellular lipids in the aorta. Plaques were also more
advanced and with a greater content of smooth muscle
cells in the coronaries. Interestingly, the burden of athero-
sclerotic lesions correlated with the percentage of alveolar
macrophages positive for particles.
The effects of inhaled PM2.5 on aortic atherosclerosis have
been assessed on apoE null mice subject to long-term
exposures to concentrated ambient particles (CAPs) per-
formed at the A.J. Lanza Exposure Laboratory of New York
University in Tuxedo, NY (Table 3). The first study
reported in 2005 showed that 39-41 week-old apoE-/-
mice fed a chow diet and exposed to 10× ambient concen-
trations of PM2.5 for 6 hours per day, 5 days per week for
5 months exhibited a 57% increase in the percentage of
atherosclerotic plaque area in the aortic root [41] (Table 3,
Figure 3). However, there were no differential effects in
the context of extreme hyperlipidemia exhibited by apoE-
/-, LDL-/- mice exposed to the same conditions [41]. A sec-
ond study reported the same year showed that younger 6-
week-old apoE-/- mice fed a chow diet and exposed to sim-
ilar conditions for 6 months displayed a 45% increase in
the percentage of aortic atherosclerotic plaque area that
was not statistically significant [42]. In this study, how-
ever, marked hyperlipidemia achieved by the feeding of a
high fat diet resulted in a greater and significant promo-
tion of atherosclerosis as CAPs-exposed mice showed a
58% significant increase in aortic root plaque area (Figure
3) [42], together with impaired vasomotor response.
More recently, a third study of apoE-/- mice fed a high fat
diet and exposed to PM2.5 in the same facility confirmed
the enhancement of aortic atherosclerosis as assessed by
the percentage of the plaque area in the aortic arch by
ultrasound bio-microscopy [43] (Table 3, Figure 3). In
this study, PM2.5 exposures also led to atherosclerotic
plaques that were richer in tissue factor [43], which could
play a causative role or simply be an indicator of greater
atherosclerotic plaque burden. One limitation of these
studies is the relatively small number of sex-matched ani-
mals (n < 10/group) used to assess vascular pathology that
has a large phenotypic variance. However, the consistent
reproducibility of PM2.5 proatherogenic effects in all three
studies decrease the potential for type I error.
In another animal study in the Southern California Parti-
cle Center space (SCPC) and the University of California
in Los Angeles (Table 3) [44], we tested the notion that the
oxidant potential and size of ambient particles play an
Table 3: Animal studies evaluating the effect of air pollution on atherosclerosis
Study PM fraction 
(mode of 
administration)
Animal model Diet Assessment of 
Atherosclerosis 
(Method)
Effect on 
atherosclerosis
Reference
Suwa et al
2002
PM10 (I.T.) Watanabe rabbits Chow % lesional volume in 
coronary arteries and aorta 
(histology)
Increase [38]
Chen & Nadziejko
2005
PM2.5
(Inhaled CAPs)
apoE-/-, LDL-/- mice
apoE-/- mice
Chow
Chow
% lesional area in whole 
aorta (histology)
No change
Increase
[41]
Sun et al 2005 PM2.5
(Inhaled CAPs)
apoE-/- mice Chow
HFD
% lesional area in cross-
sections of aorta (histology)
N.S. increase
Increase
[42]
Sun et al
2008
PM2.5
(Inhaled CAPs)
apoE-/- mice Chow
HFD
% lesional area in aorta 
(ultrasound)
N.S. increase
Increase
[43]
Araujo et al
2008
PM2.5 & UFP 
(Inhaled CAPs)
apoE-/-mice Chow
Chow
Mean lesional area in aortic 
root (histology)
N.S. increase
Increase
[44]
I.T. = Intratraqueal, CAPs = Concentrated ambient particles, HFD = High fat diet, N.S. = Not significantParticle and Fibre Toxicology 2009, 6:24 http://www.particleandfibretoxicology.com/content/6/1/24
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important role in determining atherosclerotic lesion
development, with a hypothesis that UFP should trigger
more plaque development than bigger particles thanks to
their greater prooxidant potential, as it will be discussed
below. Araujo et al exposed apoE-/- mice fed a chow diet to
concentrated PM2.5, UFP or filtered air for 5 hours/day, 3
days per week for 5 weeks. UFP-exposed mice developed
25% and 55% more aortic atherosclerosis, assessed by the
mean atherosclerotic lesional area in the aortic root, com-
pared to PM2.5  or FA-exposed mice, respectively [44].
Although PM2.5 exposures tended to enhance lesion for-
mation over FA controls, resulting in a 23% increment in
lesional area, these effects were relatively smaller than in
the previous studies (Figure 3). One possible explanation
could be the shorter duration of exposures (5 weeks
instead of 5-6 months). This is exemplified by the data in
Figure 3 showing that the degree of PM2.5-induced athero-
genesis increases with the length of the exposures. In addi-
tion, the magnitude of these effects is enhanced by UFP
exposures to yield a comparable degree of atherosclerosis
enhancement as long-term PM2.5 exposures (Figure 3).
One limitation of the SCPC study is that the concentrator
technology employed (VACES: Versatile Aerosol Concen-
tration Enrichment System) generates overlapping CAPs
aerosols. The fact that the sub-2.5 μm aerosol included
UFP made straight comparison with the UFP aerosol dif-
ficult since particle mass in the former aerosol was mostly
determined by the accumulation mode particles (0.1-2.5
μm). The more abundant UFP contributed to less than a
fifth of the PM2.5 aerosol's total mass. It is possible that the
true relative proatherogenic effects of UFP, compared to
the larger 0.1-2.5 μm particles are bigger than can be
inferred from our study. When normalized by mass,
atherosclerotic lesion scores of UFP-exposed mice were
460% greater than scores exhibited by PM2.5-exposed
mice, an extrapolation that is not entirely adequate given
that both aerosols overlapped in size. On the other hand,
the UFP aerosol contained 44% more particles than the
number of sub-0.18 μm particles present in the PM2.5 aer-
osol which could explain the observed difference, pro-
vided that the sub-0.18 μm components accounted for all
or most of the PM2.5-induced proatherogenic effects. Any
of these extrapolations could enhance the approximately
25% difference in the proatherogenic potentials of UFP
versus the larger 0.1-2.5 μm particles. An accurate estimate
of the relative potency of UFP vs. 0.1-2.5 μm particles
would require a different concentrator technology with
selective exposures to UFP and 0.1-2.5 μm particles as well
as the use of four parallel exposure groups where both par-
ticle mass and particle number concentrations were
matched to quantify the relative importance of UFP.
An additional limitation of this study is that it only evalu-
ated a single dose at only one time point, which impedes
the assessment of threshold, latency of effects or potency.
Furthermore, the particles collected in Los Angeles have
not been compared to other locations in the world where
unique aerosol compositions in each size range could
have different outcomes. It will be important to conduct
similar studies in different places where the effects of dif-
ferent particle compositions on atherosclerosis, not only
size, can be assessed.
Proposed oxidative stress paradigm for 
understanding of PM proatherogenic effects
A number of mechanisms have been proposed to explain
the cardiovascular effects of ambient PM (Figure 2), which
has been the subject of recent extensive reviews [5,6,45].
At the cellular level, these various mechanisms involve
free radical production (by transition metals and organic
compounds), oxidative stress, cytokine release, inflamma-
tion, endotoxin-mediated damage, stimulation of capsai-
cin receptors, autonomic nervous system activity, covalent
modification of key cellular molecules and increased pro-
coagulant activity [5,6,45,46].
Diesel exhaust particles (DEP) have been used as a model
pollutant and extensively studied in airway inflammation.
We and others have shown that the pro-inflammatory
PM2.5 effects on atherosclerotic lesions in animal studies Figure 3
PM effects on atherosclerotic lesions in animal stud-
ies. The relative increment in atherosclerotic lesions induced 
by PM exposures over filtered-air controls is displayed (%) 
Atherosclerotic lesions were assessed by histological analysis 
of aortic cross-sections, en-face assessment of the whole 
aorta or ultrasound biomicroscopy depending on the study. 
Mode of atherosclerotic lesion assessment and references 
for each study are shown in Table 3. HFD = High fat diet. * p 
< 0.05 in comparison with the corresponding filtered-air 
controls.
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effects of DEP and concentrated air particles (CAPs), that
result in enhancement of allergic inflammation [47,48],
acute asthma exacerbation and bronchitis flares [3,49] are
linked to ROS production [46,48,50]. This includes O2.-
production in macrophages, bronchial epithelial cells and
lung microsomes incubated with the particles or their
organic extracts [51,52]. Moreover, we have demonstrated
that thiol antioxidants, which are highly effective in sup-
pressing reactive oxygen species (ROS) production by
organic DEP chemicals in vitro, interfere in the adjuvant
effects of DEP in a murine allergen sensitization model
[53]. We have shown evidence that DEP induce oxidative
stress and cellular effects in target cells that can be better
understood according to a stratified oxidative stress
model, aka as the hierarchical oxidative stress hypothesis
[54] (Figure 4). When ROS production overwhelms the
antioxidant defenses, a state of cellular oxidative stress
develops [55], characterized by a depletion of intracellular
GSH, leading to GSSG accumulation and a drop in the
GSH/GSSG ratio [55]. This state of redox disequilibrium
initiates additional redox-sensitive signaling pathways,
including activation of several MAP kinases as well as the
NF-κB cascade. These cascades act in synergistic fashion to
activate cytokine and adhesion molecule expression
through appropriate promoter response elements.
Indeed, a number of laboratories have demonstrated that
DEP and ambient PM induce JNK, p38MAPK and NF-κB
activities, which are functionally linked to the cytokine
and chemokine production in vivo and in vitro [56,57].
DEP has also been shown to elicit ROS production in vas-
cular cells such as pulmonary artery endothelial cells [58],
rat heart microvessel endothelial cells [59] and human
microvascular endothelial cells [60]. Furthermore, it
appears that DEP could induce oxidative stress, inflamma-
tory and propapoptotic signals in endothelial cells in a
dose-dependent hierarchical fashion as incremental DEP
concentrations result in a larger recruitment of genes and
toxicity [60].
We have shown that the aromatic and polar DEP frac-
tions, which are enriched in polycyclic aromatic hydrocar-
bons (PAHs) and quinones, respectively, are most active
in the induction of heme oxygenase 1 (HO-1), glutath-
ione S-transferase (GST), and other phase II enzymes that
correspond to the first tier of defense in macrophages (Fig-
ure 4) and epithelial cells [61]. We have also demon-
strated that the triggering of this antioxidant defense is
regulated by the transcription factor p45-NFE2 related
transcription factor 2 (Nrf2) by modulation of its protea-
somal degradation in the cytosol and translocation into
the nucleus [61]. Interestingly, ambient PM also triggers
Nrf2-regulated genes in response to its content of prooxi-
dative and electrophilic chemicals. Various particle sizes
have marked differences in their chemical composition as
a result of their different sources of origin and modes of
generation previously described. These differences result
in different redox activity and ability to cause mitochon-
drial damage as shown in Table 4. Thus, ambient UFP trig-
gers the induction of Nrf2-regulated HO-1 in
macrophages to a greater degree than ambient PM2.5 or
coarse particles [61]. The same can also be shown in vivo
using a transgenic mouse model in which the heme oxy-
genase promoter was linked to a luciferase reporter gene
[62]. Exposure of these animals in a mobile animal trailer
showed that the promoter reporter gene construct is more
readily induced in animals exposed to concentrated UFP
compared to animals simultaneously exposed to a con-
centrated atmosphere of PM2.5 or filtered air (Figure 5).
This greater responsiveness was in relation with the
greater prooxidant potential of ultrafine PM due to their
higher content of redox cycling organic compounds.
UFP exhibit greater relative content of elemental and
organic carbon [44,63] that vary depending on the
sources. Urban UFP contain a higher content per unit
mass of polycyclic aromatic hydrocarbons (PAH), which
are relevant organic constituents since they can induce
Stratified hierarchical response to air pollutants Figure 4
Stratified hierarchical response to air pollutants. Mac-
rophages exposed to particulate matter components (e.g. 
DEP) respond in a dose-dependent fashion via the activation 
of pathways and mechanisms at various levels of action 
(tiers). For example, Nrf2 can induce the transcription of 
antioxidant genes via the antioxidant response element 
(ARE) in the earliest level of defense (tier 1). When the 
mechanisms of defense involved in one tier are not sufficient 
to contain the injurious stimuli, signaling pathways of the sub-
sequent(s) tier of action may get activated, such as MAPK 
pathways that regulate proinflammatory genes via Activating 
Protein (AP) transcription factors (tier 2) or proapoptotic 
signals triggered by mitochondrial perturbation that can lead 
to activation of the mitochondrial permeability transition 
(PT) pore and cellular toxicity (tier 3). Modified from Li et al 
[123].
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oxidative stress and electrophilic chemistry in tissues
[46,64] after conversion to quinones by the involvement
of cytochrome P450 1A1, epoxide hydrolase and dihydro-
diol dehydrogenase [65]. Some quinone species can act as
redox cycling catalysts, leading to the formation of O2,-
when undergoing one-electron reductions by NADPH
cytochrome P450 reductase to form semiquinones [66]
and recycling to the original quinones [50,66]. There is an
excellent correlation between the PAH content of UFP and
their ability to engage in redox cycling reactions in-vitro.
Indeed, UFP samples from the Los Angeles basin are more
potent than PM2.5 or coarse PM at inducing oxidative
stress as measured by the dithiothreitol (DTT) assay,
extent of HO-1 induction, reduced glutathione to oxi-
dized glutathione (GSH/GSSG) ratios and the ability to
cause mitochondrial damage (Table 4). These biological
endpoints are correlated to greater organic PM carbon and
PAH contents, suggesting a role of these organic sub-
stances in generating redox activity [67-69]. Furthermore,
UFP collected from various locations differ significantly in
their ability to trigger Nrf2-regulated responses, also in
strong relation with their chemical composition and elec-
trophilic potential [67]. Thus, the greater prooxidant
effects of the smaller particles appear to be partly derived
from their higher content of prooxidant compounds.
PM ability to induce ROS generation appears to be key in
promoting atherosclerosis, which could be the result of
PM-mediated systemic prooxidant and proinflammatory
effects. Atherosclerosis is a vascular inflammatory process
where lipid deposition and oxidation in the artery wall
constitutes a disease hallmark [39,40,70-73] (Figure 6).
Infiltrating lipids come from low density lipoprotein
(LDL) particles that travel into the arterial wall and get
trapped in a three-dimensional cage-work of extracellular
fibers and fibrils in the subendothelial space [74,75],
Table 4: Characteristics of PM fractions
Parameter Coarse (PM2.5-10)F i n e  ( P M 2.5)U l t r a f i n e
Size (μm) 2.5 - 10 0.15 - 2.5 < 0.15 μm
Number per μm3 + ++ +++
Mass (μg) per μm3 +++ ++ +
Relative content (% of total mass) *
Elemental carbon + ++ +++
Organic carbon + ++ +++
PAHs + + +++
Metals +++ ++ +
Redox activity + ++ +++
DTT assay ** + ++ +++
HO-1 induction# + ++ +++
GSH depletion # + +++ +++
Mitochondrial damage# None Some Extensive
Surface area + ++ +++
Bioavailability of active compounds + ++ +++
Lung penetrability + ++ +++
Modified from Li et al [123]. * Relative content was estimated using mass concentration and fractional composition of CAPs collected on Teflon and 
quartz filters in two locations from the Los Angeles basin as reported [67]. ** DTT assay was performed on similar CAPs samples [67]. # HO-1 
induction, GSH depletion and mitochondrial damage were determined in a murine macrophage cell line (RAW 264.7) and a transformed human 
bronchial epithelial cell line (BEAS-2B) exposed to similar CAPs samples [67].Particle and Fibre Toxicology 2009, 6:24 http://www.particleandfibretoxicology.com/content/6/1/24
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where they are subject to oxidative modifications [76-78]
leading to the generation of "minimally modified" LDL
(mm-LDL). Such oxidized LDL is capable of activating the
overlying endothelial cells to produce pro-inflammatory
molecules such as adhesion molecules, macrophage col-
ony-stimulating factor (M-CSF) and monocyte chemotac-
tic protein-1 (MCP-1) [79-81] that contribute to
atherogenesis by recruiting additional monocytes and
inducing macrophage differentiation [70,71,73]. Later
stages of the disease involve the proliferation of smooth
muscle cells, formation of fibrous caps, induction of
apoptosis, hemorrhage and calcification [73]. Animal
models have been useful not only to demonstrate the PM
proatherosclerotic effects as described in the previous sec-
tion, but also to get some insights into the possible mech-
anisms involved. It is possible that the different
proatherogenic effects of particles of different sizes and
compositions could at least be partly related to their dif-
ferent abilities to elicit prooxidant and proinflammatory
reactions in vascular cells.
How do the prooxidative effects of PM promote 
atherogenesis?
The promotion of atherogenesis by PM is likely the result
of systemic prooxidant and proinflammatory effects at
vascular sites. In support of this notion, Nurkiewicz et al
have shown that intratracheal instillation of residual oil
fly ash (ROFA) [82,83] in rats led to greater vascular ROS
generation, as assessed by the tetranitrobluetetrazolium
(TNBT) reduction method [82], resulting in a dose-
dependent impairment of systemic endothelium-depend-
ent arterial dilation, increased leukocyte rolling and adhe-
sion as well as deposition of myeloperoxidase in the
spinotrapezius muscle microcirculation [82,83]. Likewise,
long-term PM2.5 inhaled exposures that promote athero-
sclerosis, also lead to enhanced ROS generation in the aor-
tic plaques and increased formation of 3-nitrotyrosine
residues [42].
Ambient UFP triggers prooxidant effects in-vivo Figure 5
Ambient UFP triggers prooxidant effects in-vivo. Rep-
resentative dorsal photograph of HO-luc transgenic mice that 
were exposed to concentrated UFP, concentrated PM2.5 or 
filtered-air (FA) for 5 hours in a mobile exposure laboratory 
located in downtown Los Angeles, ~300 meters away from 
the I-110 freeway. Increased bioluminescence was due to a 
larger HO-1 upregulation response generated in tissues sub-
ject to greater oxidative stress. Mice were generated and 
obtained from Dr. Christopher Contag at Stanford Univer-
sity [62]. They contain a modified coding sequence of the 
luciferase gene under the control of the full HO-1 promoter. 
Whole-body images were acquired within 3 hours of the 
exposure using a cooled charged-couple device (CCD) cam-
era at the Small Animal Imaging Center of the UCLA Crump 
Institute for Molecular Imaging [124] as previously described 
[125]. The bioluminescence signal was recorded as maximum 
photons/sec/cm2/steradian (p/sec/cm2/sr). Notice that the 
UFP-exposed mouse displays increased luciferase emissions 
both in the thorax and abdomen as compared with the PM2.5 
or FA-exposed mice.
Pathogenesis of atherosclerosis Figure 6
Pathogenesis of atherosclerosis. Lipid infiltration of the 
artery wall originating from circulating LDL followed by oxi-
dative modification in the subendothelial space, monocyte 
chemotaxis and foam cell formation are among the earliest 
events in atherogenesis. Monocytes differentiate into macro-
phages, followed by release of inflammatory mediators and a 
vicious cycle of inflammation. More advance stages of the dis-
ease include smooth muscle cell proliferation, formation of 
fibrous caps, necrotic cores, calcification, rupture, hemor-
rhage and thrombosis. Possible mechanisms how PM 
enhances atherosclerosis include: 1) Systemically translo-
cated UFP or their chemical constituents may synergize with 
ox-PAPC generated within ox-LDL in the activation of 
proatherogenic molecular pathways in endothelial cells, 2) 
Inflammatory mediators released from the lungs may pro-
mote monocyte chemotaxis into the vessels, 3) PM can 
induce HDL dysfunction with loss of its antiinflammatory 
properties. Modified from Araujo and Lusis [126].
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How does PM inhalation in the lung lead to the systemic
effects on the vasculature?. One possibility is that prooxi-
dant PM deposited in the lungs lead to the release of
proinflammatory cytokines (Figure 6) into the blood
stream by a series of steps such as: a) Deposition of
inhaled particles in the respiratory tract, b) Ability to trig-
ger or enhance free-radical production, c) Development of
pulmonary inflammation, d) Release of inflammatory
mediators into the systemic circulation. Inhaled small
particles deposit in the respiratory tract via diffusion due
to displacement when they collide with air molecules
[84]. According to the International Commission on Radi-
ological Protection (IRCP) 1994 model for particle depo-
sition in the respiratory tract [85], inhaled particles
deposit in various segments of the human respiratory tract
that can be grossly divided into three anatomical regions:
the nasopharyngeal, tracheobronchial and alveolar
regions [85]. Once particles get deposited in the lungs,
they could trigger or enhance ROS formation when in
contact with epithelial cells, alveolar macrophages, pneu-
mocytes, etc. as discussed in the previous section. This
could lead to development of interstitial and/or alveolar
inflammation with the subsequent release of inflamma-
tory mediators into the systemic circulation. While parti-
cle deposition (step a) has been amply studied in both
animals and humans as well as their ability to induce free
radical reactions in pulmonary cells (step b), the remain-
ing steps c and d are still awaiting definite confirmation.
There is clear evidence that particle deposition can lead to
systemic inflammatory events. Suwa et al reported that
their PM10-exposed animals exhibited elevation of poly-
morphonuclear cells and circulating band cell counts 2
weeks after starting the exposures, with an increase in the
size of the bone marrow mitotic pool as assessed by BrdU-
labeling [38]. Although they claimed that their work sup-
port the notion of PM-induced systemic inflammation in
response to local pulmonary inflammation, they did not
provide evidence of increased systemic proinflammatory
markers that could be linked to both effects. Likewise,
none of the CAPs studies provided direct evidence for
such mediators in apoE-/- mice. However, a recent study of
C57BL6 mice exposed to CAPs for 6 months did result in
increased plasma concentrations of inflammatory
biomarkers such as tumor necrosis factor-α (TNF-α),
interleukin-6 (IL-6), E-selectin and intracellular adhesion
molecule-1 (ICAM-1), indicative of systemic inflamma-
tory effects [86]. In that study, PM2.5 exposures also led to
increased visceral adiposity and insulin resistance, sug-
gesting a possible link between air pollutants and type 2
diabetes mellitus [86]. Despite the lack for direct evidence
of systemic inflammatory mediators in apoE-/-  mice,
Araujo et al showed that CAPs exposures led to the devel-
opment of dysfunctional HDL with a decrease or loss of its
anti-inflammatory properties as exhibited by PM2.5 and
UFP-exposed mice, respectively [44]. Furthermore, UFP
exposures led to HDL that exhibited proinflammatory
properties and could therefore contribute to enhanced
disease pathogenesis (Figure 6).
PM-mediated generation of dysfunctional HDL could
boost and propagate systemic inflammatory effects or at
least function as a marker of systemic inflammation. It is
well established that plasma HDL cholesterol and apoA1
levels are inversely correlated with the risk for coronary
artery disease [87-89]. In addition to the well-character-
ized ability to promote reverse cholesterol transport [90],
HDL has been reported to have antioxidant, antiinflam-
matory and antithrombotic activities [91-93]. However,
high levels are not always protective in subjects, suggest-
ing that not all HDLs prevent atherosclerosis [94]. Fur-
thermore, dysfunctional proinflammatory HDL may serve
as a useful marker for predicting susceptibility for athero-
sclerosis in humans [95] and in rabbits [96], where it has
been found to be a better predictor han total or LDL cho-
lesterol levels. Thus, it will be necessary to characterize the
type of alterations that PM exposures induce in HDL par-
ticles and confirm whether those happen in human sub-
jects also. This can help to elucidate pathogenesis and may
even lead to the identification of a potential biomarker.
Interestingly, these proinflammatory effects occurred in
the absence of significant pulmonary inflammation
which raises the possibility that the lungs might not need
to be an active player or mediator in the induction of sys-
temic vascular inflammation. Alternatively, particles
could be endocytosed by alveolar macrophages (Figure 7),
which could trigger activation of molecular inflammatory
pathways that could be transduced systemically even in
the absence of obvious alveolitis or interstitial pneumoni-
tis. Another potential mechanism is that once particles get
deposited in the lungs, they could undergo transcytosis
across epithelia of the respiratory tract into the intersti-
tium and access the blood circulation directly or via lym-
phatics (Figure 6), or could be taken up by sensory nerve
endings embedded in airway epithelia, followed by
axonal translocation to ganglionic and CNS structures
[84]. While there are multiple reports that support the
notion of systemic translocation of synthetic nanoparti-
cles in experimental models [52,97,98] and humans [99],
no convincing demonstration has been provided about
this route for inhaled ambient particles. In addition, in
case nanoparticles do translocate to the systemic circula-
tion, no studies have shown that the translocated particles
actually reach or deposit in blood vessels, perhaps due to
the inability to detect them at these sites because of small
size. There could be alternative ports of entry such as
ingestion and absorption via the gastrointestinal tract or
direct contact through dermal exposure [84]. However,
there is no direct evidence for the significance of theseParticle and Fibre Toxicology 2009, 6:24 http://www.particleandfibretoxicology.com/content/6/1/24
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routes in the exposure to ambient particles and although
their feasibility has been supported by studies with engi-
neered nanoparticles, these are particles that fall outside
the scope of this review.
An alternative possibility is that particles deposited in the
lungs get internalized into the cells (e.g. endocytosis by
alveolar macrophages) and their chemicals could get
translocated into the systemic circulation allowing them
to reach target tissues (Figure 6). Whether the whole par-
ticles or chemical constituents access the systemic targets,
they can activate important proatherogenic molecular
pathways once in contact with cells from the vascular
endothelium [60]. Although we have not found direct evi-
dence for increased aortic oxidative stress, we showed that
both PM2.5 and UFP exposures led to increased hepatic
oxidative stress [44]. In addition, UFP triggered the upreg-
ulation of Nrf2-regulated antioxidant genes and unfolded
protein response (UPR) genes in the liver, suggesting that
PM exposure leads to both systemic prooxidant and
proinflammatory effects [44].
It is clear that inhaled particles do get deposited in the
lungs (step a), with the potential to exert prooxidative
effects and activate molecular pathways in response (step
b), even in the absence of obvious clinical inflammation
(step c). Somehow, systemic vascular inflammation and
prooxidative effects follow via a mechanism(s) still to be
elucidated. In addition, oxidative stress and inflammation
are strongly connected and either one can lead to the
other. It is likely that the prooxidant potential of ambient
particles determine their ability to activate pathways that
lead to prooxidant and proinflammatory effects in the
vasculature and promotion of atherosclerosis. However,
in spite of this logical inference, it still remains unclear
whether PM-induced prooxidant effects trigger or are the
consequence of vascular inflammatory effects. Further
research is required to elucidate these mechanisms and to
prove whether particle-mediated proinflammatory effects
are due indeed to its prooxidant potential.
Why are UFP more proatherogenic than PM2.5?
A number of factors other than particle size need to be
considered to explain why UFP may be more atherogenic
than PM 2.5 (Table 4, Figure 8). This includes considera-
tion of particle numbers, physicochemical composition,
prooxidant potential, bioavailability and pulmonary
retention. A brief discussion of how these factors could
contribute to the increased atherogenic potential of UFP
include:
a) Larger particle number
Exposure to PM has been traditionally assessed by meas-
ures of mass per space (e.g. daily, annual, average or peak
μg/m3). Adverse health effects have been correlated line-
arly with various measures of exposure, without any clear
threshold below which PM levels have been found to be
consistently safe [7,8,100]. However, particles < 0.1-0.2
μm, which contribute very little to overall PM2.5 mass, rep-
resent > 85-90% of the total PM2.5 particle number [101].
Therefore, it is conceivable that larger particle numbers in
UFP atmospheres, despite a smaller mass, could result in
larger biological effects. In our study, development of
larger atherosclerotic lesions in the UFP exposures corre-
lated with increased particle numbers rather than with PM
mass. Thus, the 25% increase in atherosclerotic lesion area
in UFP vs. PM2.5-exposed mice occurred in parallel with a
44% increase in the number of particles < 0.18 μm in spite
of a 4-fold smaller PM mass [44].
b) Larger content of redox active compounds
PM is composed of hundreds of organic chemicals and
transition metals that could trigger or exacerbate free rad-
ical reactions contributing to systemic proatherogenic
effects. As discussed in section 3, UFP are enriched in
organic carbon content as well as prooxidative PAHs
(Table 4) that promote oxidative stress and inflammation.
This could explain the increase in atherosclerotic lesion
development. Whether or not these compounds are the
actual toxicants contributing to atherogenesis, they may
UFP are endocytosed by alveolar macrophages Figure 7
UFP are endocytosed by alveolar macrophages. Elec-
tron microscopy photographs of a lipid-laden alveolar macro-
phage harvested from an apoE-/- mouse exposed to 
concentrated ambient ultrafine particles (<0.18 μm). Red 
arrows indicate electron-dense material corresponding to 
intracellular aggregates of nanoparticles. Notice the subcellu-
lar mitochondrial localization encircled by the red dotting. 
Source: Journal cover of Araujo et al [44].Particle and Fibre Toxicology 2009, 6:24 http://www.particleandfibretoxicology.com/content/6/1/24
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serve as a proxy for the substances ultimately involved. For
instance, PAHs can be converted to quinones and other
redox cycling substances. In addition, it appears that while
transition metals are also important catalysts for free rad-
ical reactions in-vitro, they may be less critical for the in-
vivo systemic effects, as UFP exhibited greater proathero-
genic potential despite a lower metal content than PM2.5
[44].
c) Greater bioavailability
An important feature derived from the small size of UFP
is that their large surface-to-mass ratio along with
increased number could lead to a sizable increase in bio-
available surface [102]. The number of atoms or mole-
cules that are displayed and packaged on the surface of
particles increase exponentially as the size shrinks below
100 nm [84]. Thus, the presence of bioreactive chemicals
(e.g. PAHs, transition metals) on the large surface area of
UFP could make these chemicals more bioavailable at the
contact sites of the particles with cells and tissues where
prooxidant effects take place (Figure 8). The surface area
or more accurately the bioreactive surface area of UFP con-
stitutes an exposure parameter that may more accurately
depict small particle dosimetry than the current calcula-
tion of PM exposure by mass [31,103,104]. Unfortunately
there are no easy ways to calculate reactive surface area at
present.
d) Greater lung retention
Small particle size allows better penetration and diffusion
into the lungs according to the IRCP 1994 model for par-
ticle deposition in the respiratory tract [85]. The fractional
deposition of particles during nose breathing into the
three anatomical regions in this model (nasopharyngeal,
tracheobronchial and alveolar regions) varies significantly
depending on the aerodynamic diameter of the inhaled
particles, respiratory frequency, pattern of breathing and
respiratory co-morbid conditions. Indeed, UFP exhibit a
greater fractional deposition in the tracheobronchial and
alveolar regions than larger particles. For instance, 20-nm
synthetic particles, which correspond to the particle peak
size of ambient urban aerosols, exhibit the highest frac-
tional deposition efficiency in the alveolar region (~50%)
[84,102]. In addition, the UFP fractional deposition
increases markedly during exercise in healthy subjects
[105] when the respiratory frequency is greater and the
pattern of breathing is altered. Furthermore, pulmonary
conditions such as chronic obstructive pulmonary disease
(COPD) or asthma that are characterized by airway con-
striction with changes in air flow dynamics and increases
in lung residual volume, have been shown to result in
increased fractional deposition of UFP [106,107], likely as
a result of greater contact with the airway wall and
enhanced diffusional deposition. Better airway deposition
could translate into better retention, cellular uptake and
greater propensity to induce systemic effects, a notion that
remains to be proven. The greater retention of UFP could
be partly due to increased Van der Waals forces or electro-
static interactions, all of which contributes to "adhesive
interactions" [108,109]. Once deposited in the alveoli,
particles are wetted by the surfactant film and could be
taken up by alveolar macrophages by physico-chemical
forces rather than receptor-ligand interactions that play a
role in phagocytosis of larger particles. Whether these par-
ticles or chemical constituents enter the systemic circula-
tion is a matter of intense debate that requires further
investigation. It will be important to determine whether
all these factors confer greater toxicity to UFP in human
subjects since they may imply the need for adjusting the
metrics of exposure to take account of particle number,
surface area and oxidant potential.
Relationship of PM to other proatherogenic 
factors: Gene-environment interactions
The development of PM-induced proatherogenic effects
likely depends not only on exposure characteristics such
as dose, duration and location of exposure as discussed
above but also on the differential susceptibility of exposed
individuals [110], according to a gene-environmental par-
adigm that recognizes that atherosclerosis is a complex
disease that involves a multiplicity of genetic and environ-
mental factors [73]. In fact, exposure to PM is now consid-
ered as a novel risk factor that could contribute to the
composite clinical risk in synergy with well known cardi-
Factors that may explain greater UFP's proatherogenic  potential Figure 8
Factors that may explain greater UFP's proathero-
genic potential. UFP (in red) are the smallest, most numer-
ous particles and with best pulmonary retention (top panel). 
UFP exhibit greater relative content of redox-active com-
pounds (e.g. PAHs, in green) than bigger particles (mid 
panel). UFP's greater surface-to-mass ratio may allow reac-
tive compounds (in green) to have increased localization 
towards the surface of the particle (in red) and be more bio-
available for free-radical reactions when in contact with cells 
(bottom panel). Estimates for the increased content of 
prooxidant PAHs and surface-to-mass ratio in comparison to 
PM2.5are from the SCPC study [44].
Why are the smallest particles more proatherogenic ?
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ovascular risk factors such as hypertension, hypercholeste-
rolemia, smoking, diabetes and/or obesity among others.
However, this synergy has only been studied to a limited
degree. While subjects with advanced age [111,112], obes-
ity [19] or congestive heart failure [113] have been
reported to exhibit increased susceptibility to PM-medi-
ated cardiovascular effects, only one study among those
evaluating the impact of PM on atherosclerosis found pre-
disposing conditions such as age and sex [33]. However,
the number of studies and number of subjects are very
small and it is still too early to draw any conclusions. Fur-
ther research is required with larger number of individuals
that undergo extensive characterization of clinical traits to
maximize the possibility of unveiling gene-environment
interactions.
Cellular and experimental animal work can be instrumen-
tal to identify conditions that help establish the molecular
and genetic pathways that are involved in the interaction
of PM with other risk factors. While the individual contri-
bution of air pollutants to atherogenesis might be small,
their effects could be exacerbated in synergy with other
known proatherogenic factors. These interactions could
be more evident on molecular pathways known to medi-
ate disease pathogenesis. One possibility is that PM
proatherogenic effects depend on generation of oxidative
stress. PM could exacerbate the biological activity of well-
known prooxidative and proatherogenic factors such as
ox-LDL. We tested this hypothesis by evaluating the anti-
oxidant response of microvascular endothelial cells to
DEP in the absence and presence of oxidized PAPC (1-
palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcho-
line), one of the key prooxidative components generated
in LDL particles. While both DEP and ox-PAPC have been
shown to exert prooxidative effects in vascular cells
[58,59], the combination of both stimuli synergize in
increasing antioxidant gene expression, including HO-1
[60]. In addition, analysis of the genomic profiles of cells
subjected to the various treatments unveiled a large
number of genes where the same DEP and ox-PAPC syn-
ergy was present. These genes were grouped into clusters
that were enriched in proinflammatory, apoptotic and
UPR pathways, all important players in atherogenesis.
These gene clusters are reminiscent of the different ele-
ments of the hierarchical oxidative stress paradigm dis-
cussed earlier on. Some representative examples include
proinflammatory genes such as Interleukin 8 (IL-8) and
chemokine (C-X-C motif) ligand 1 (CXCL1) production,
immune response genes such as Interleukin 11 (IL-11)
and UPR genes such as activating transcription factor 4
(ATF 4), heat shock 70 kDa protein 8 (HSPA8) and X-box
binding protein 1 (XBP1). Importantly, some of these
same genes were found to be preferentially upregulated in
the livers of apoE-/-mice exposed to UFP, supporting the
validity of in-vitro generated data to predict relevant in-vivo
outcomes.
The identification of participant gene pathways would
pave the way to study gene-environment interactions in
the development of PM proatherogenic effects. For
instance, it is conceivable that modulation in the expres-
sion levels of antioxidant genes as a result of gene poly-
morphisms could alter the magnitude of effects caused by
PM. Indeed, polymorphic variants of the glutathione-S-
transferase genes GSTP1 and GSTM1 [114] or HO-1 [115]
have been reported to influence the risk of developing
new onset asthma associated to air pollutants. It appears
that gene-gene and gene-environment interactions could
determine the fate of individuals to develop new disease
under specific circumstances. Thus, in a population-based
cohort study in Southern California, child carriers of the
short GT-repeat polymorphism that results in higher HO-
1 expression, exhibited decreased risk of new-onset
asthma as compared with carriers of the non short GT alle-
les [115]. This association was only present in non-his-
panic white children but not in hispanic subjects and
especially among those residing in low ozone communi-
ties. These findings illustrate the high level of complexity
present in the interaction between genetic and environ-
mental factors that could be similar to the interactions
between particulate pollutants and atherosclerosis-related
genes. Interestingly, one study reported inverse associa-
tions of exposure to primary aerosols with the antioxidant
erythrocyte enzyme Cu/Zn-SOD and GPx-1 in subjects
with coronary artery disease [36]. Polymorphisms and
variations in the expression of these phase 2 enzymes
could potentially lead to increased susceptibility to
adverse cardiovascular events. It is therefore necessary to
perform large-scale studies where in addition to detailed
characterization of pollutant exposures, individuals are
genotyped and extensively phenotyped for clinical traits
and gene expression levels. This will enhance our under-
standing of individual susceptibility to PM-mediated
adverse cardiovascular effects and may also shed light on
the adaptation mechanisms of people who live in a pol-
luted environment.
Multi-pollutant effects contributing to 
atherosclerosis
Although most of the published data attributes the cardi-
ovascular effects to the particulate matter components,
these associations have been questioned on the basis of
publication bias. While it is extremely unlikely that publi-
cation bias could explain the overall consistency, coher-
ence and strength of those associations [6,116], it is
conceivable that other co-pollutants could play a role.
Work from the Lovelace Respiratory Institute has shown
that exposure of apoE-/- mice to both whole and particle-
free gasoline exhausts results in the induction of aorticParticle and Fibre Toxicology 2009, 6:24 http://www.particleandfibretoxicology.com/content/6/1/24
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metalloproteinases (MMP)-2 and -9 after 7 weeks [117]
and as early as after 7 days [118]. This suggests that gase-
ous components are responsible for those effects. Interest-
ingly, gasoline exhaust emissions appear to trigger both
ROS and endothelin 1 (ET-1) mediated pathways with a
complex degree of interconnectivity. Increased expression
and activity of MMP-9 was shown to be ET-1 mediated
and also present in a small cohort of humans exposed to
diesel exhausts [118]. While ET-1-mediated pathways trig-
gered by either gasoline and/or diesel exhausts could play
a role in atherogenesis, increased MMP-9 could be modu-
lating plaque stability [119] and induce plaque rupture
and subsequent development of acute coronary syn-
dromes [120]. It is possible thus that gaseous and particu-
late pollutants could exert different but cooperative
effects, which will need to be explored in more details in
the future.
Future research perspectives
We have seen in recent years an enormous improvement
in our understanding of the cardiovascular effects of air
pollution. Human epidemiological studies together with
experimental animal data discussed above support a
causal association between air PM and atherosclerosis.
Consequently, PM exposure is now considered a novel
risk factor [5]. Much work is still needed however, in the
identification of those factors that are clinically relevant.
This work will require the collaboration of investigators
from diverse disciplines that span from epidemiology,
toxicology and engineering to pathology, genetics, vascu-
lar and molecular biology. Better understanding of the
toxic air components, toxicology and pathogenesis will
allow us to formulate better ways to monitor and control
air pollution as well as to avoid or decrease their effects on
cardiovascular health.
Although most of the epidemiological work has been
focused on PM mass exposure parameters of the various
size fractions, other physicochemical parameters such as
chemical composition, particle number, surface area, sur-
face-to-mass area need to be considered in future studies
as discussed above. It may require us to develop new
parameters or composite metrics that can combine all
these various factors to best capture the overall PM-related
cardiovascular toxicity. This may help to elucidate why
exposure to PM, in strong association with CV events in
the Northeast, Midwest and Southern U.S. regions,
appears not be associated with excess risk in the North-
western U.S. regions [121,122].
Animal data that supports the notion of UFP's greater
proatherogenic potential and development of HDL dys-
function are based on one single study [44] and require
confirmation by further studies, including in human sub-
jects. Dose-response studies are also needed to determine
various toxicological parameters (e.g. threshold, latency
of effects, etc.) and whether proatherogenic effects are in
relation to the whole burden of PM exposure or the kinet-
ics of those exposures. Since air pollutants include hun-
dreds of different compounds, it is unlikely that one
single or a few chemical constituents could be responsible
for all pathogenic effects but it could be possible to iden-
tify groups of compounds that work in an additive or syn-
ergistic fashion (e.g. PAHs).
While exposure to PM leads to both prooxidant and
proinflammatory effects, there is a great degree of inter-
connection in between oxidative stress and vascular
inflammation that makes it very difficult to determine
whether the induction of vascular oxidative stress pre-
cedes or follows inflammation as discussed above. The
use of antioxidants as well as transgenics or knockouts for
critical antioxidant genes or transcription factors (e.g.
Nrf2, HO-1, superoxide dismutase) or prooxidant genes
(e.g. NADPH oxidase) may help to clarify this. Since the
portal of entry may determine the pathogenic mechanism
and the mode for transduction into systemic effects, it will
be important to fully characterized the role of the lungs as
a mediator and to assess alternative ports of entry such as
the gastrointestinal tract by ingestion of particles or skin
by contact.
Exposure to PM likely leads to important gene-environ-
ment interactions that will need to be addressed in both
human and animal studies to better define conditions of
increased susceptibility. The use of gene profiling, analysis
of gene expression by system biology approaches, geneti-
cally-engineered animals as well as mouse and human
whole genome association approaches are needed to
identify genes and/or pathways that either mediate the
effects of air pollutants, are influenced by them or could
be targeted for intervention in the future.
Conclusions
Cumulative epidemiological data support the association
of exposure to air pollution with cardiovascular morbidity
and mortality, mostly in relation to its particulate matter
components. Experimental animal work using hypercho-
lesterolemic rabbits and apoE null mice shows that ambi-
ent PM exposure promotes atherosclerosis and that the
smaller the particles, the greater the proatherogenic
effects. Enhancement of atherosclerosis correlates with the
induction of systemic prooxidant and proinflammatory
effects although the mechanism for transduction of these
effects is not clear. UFP particles may be more toxic based
on their greater number, larger content of redox active
compounds such as PAHs, greater surface-to-mass ratio
and bioavailability of chemically active constituents.
Much work is needed to better characterize the main toxic
compounds, mechanism(s) of pathogenesis, types ofParticle and Fibre Toxicology 2009, 6:24 http://www.particleandfibretoxicology.com/content/6/1/24
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genetic susceptibility that exposed individuals may
exhibit, relevant gene-environment interactions in the
induction of those effects and development of a biomar-
ker of exposure, degree of damage or susceptibility.
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